Skip to main content
Challenge 43

Thyroid Tox

Launched Awarded Completed

The aim of this Challenge is to develop a QSAR and molecular docking tool that reliably predicts thyroid receptor mediated human endocrine disruption. The tool must justify the Organisation for Economic Cooperation and Development (OECD) principles for QSAR validation to demonstrate the statistical and mechanistic reliability of the model for use in a regulatory context.

If you are interested in applying for this Challenge, please register to attend the launch webinar on Wednesday 7 September 14:00 - 15:30 (BST).

Challenge Announced

The Thyroid Tox Challenge was announced in a CRACK IT news article which can be found here

Background

There is increasing scientific, political, and public interest in the impact of endocrine effects of chemicals on human health and environmental species. Regulatory authorities are continuing to develop improved frameworks and models to predict and assess the effects of endocrine disrupting chemicals (EDCs). For example, the European Chemicals Agency (ECHA) have developed assessment criteria for identifying and classifying chemicals as EDCs that are primarily based on hazard identification [1] and in the US, the Environmental Protection Agency (EPA) are using a risk-based testing approach for EDC identification that is comprised of in vitro and in vivo tests [2]. 

EDCs may exhibit their toxicity by interacting with endocrine-related receptors such as the oestrogen, androgen, and thyroid receptors [3]. The current of endocrine testing and chemical safety regulations require in vitro testing followed by extensive in vivo testing in multiple animal species. In vitro high throughput screens that elucidate the potential interaction of EDCs with oestrogen receptors have successfully been used for EDC identification [4]. However, in vitro thyroid receptor assays are limited or lack full validation [4].

Apical endpoints related to endocrine disruption are primarily assessed using in vivo reproductive and developmental toxicity studies (e.g. hormone changes and/or histopathological changes are assessed in these tests). These endpoints are used as part of the assessment of potential thyroid receptor-mediated endocrine disruption, but it is not possible to examine the direct interaction or mechanism of action of the test chemical on the two subclasses of thyroid receptor –­­­­­­­­­­­­­­­­­ ­­­­­­­­­ alpha and beta. Most of the understanding of chemical interactions with the thyroid receptors is based on knowledge derived from the pharmaceutical and agrochemical sectors, and there is limited information on the direct interaction of petrochemicals and high production volume chemicals (chemicals that are manufactured at exceptionally high volumes and are subject to specific regulation [5, 6]) on the thyroid receptor.

QSARs are a key tool in the growing field of new approach methodologies (NAMs) that aim to better evaluate potential risks of chemicals on human health and the environment and reduce the reliance on animal models [7]. QSARs have been shown to accurately predict human health toxicities [8] and unlike current in vivo studies, can provide information on potential toxicities in a rapid and cost-efficient manner with specific information on the potential binding of chemicals to receptors prior to in vitro assays. Molecular docking enables the prediction and/or assessment of the interaction of a substance with a specific receptor. In combination, a QSAR and a molecular docking model will provide specific information on the interaction of a test chemical with the thyroid alpha and beta receptors, addressing an unmet need in endocrine disruption testing.

A QSAR and molecular docking model that can accurately predict the interaction and potential binding of petrochemicals and high volume chemicals with the thyroid alpha and beta receptors will:

  1. Permit the early identification of potential thyroid-related toxicities in chemical candidate selection without in vivo studies.
  2. Contribute to the scientific justification, along other NAMs to potentially waive studies and/or reduce animal group size of those taken forward to chemical registration.
  3. Improve the predictive capacity of required in vivo models.
  4. Decrease development cost and time to market for products containing these chemicals.

The aim of this Challenge is to develop an in silico model for predicting endocrine disruption that occurs via the thyroid receptor. It is expected that the Challenge will result in a tool that accurately and reliably predicts the interaction of a chemical with the human thyroid alpha and beta receptors using a combined QSAR and molecular docking approach.
 

3Rs benefits

If successful, this Challenge will deliver an in silico tool to replace animals used for thyroid-related endpoints in the OECD Test Guidelines (TGs) for reproductive and developmental toxicity studies. The four OECD TGs considered most informative for endocrine disruption are:

  1. The prenatal developmental toxicity study (OECD TG 414) [9].
  2. The reproduction/developmental toxicity screening test and combined repeated dose toxicity study (OECD TG 421/422) [10].
  3. The extended one-generation reproductive toxicity study (OECD TG 443) [11].
  4. The two-generation reproduction toxicity study (OECD TG 416) [12].

Collectively, these four OECD studies utilise more than 2,500 animals per chemical for regulatory registration and may take over 18 months to conduct. The reproductive and developmental toxicity studies are invasive, time-consuming, and expensive to conduct and can cause animal welfare concerns. In addition, these toxicity studies may not identify if the candidate chemical is acting directly at the thyroid alpha and beta receptors.  Removal of the thyroid apical endpoints with a detailed mechanistic tool could reduce groups sizes by 10 to 15%, which would reduce the animals used by 250 to 375 per chemical tested per company.
 

References

  1. European Chemicals Agency (2022) Hot topics: Endocrine disruptors
  2. United States Environmental Protection Agency (2021) Endocrine Disruptor Screening Program (EDSP) Overview
  3. Guarnotta V et al. Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System. International Journal of Molecular Sciences 23;23(10): 5710. doi: 10.3390/ijms23105710.
  4. United States Environmental Protection Agency (2021) Exploring ToxCast Data: Downloadable Data.
  5. United States Environmental Protection Agency (2014) High Production Volume Information System (HPVIS) (epa.gov)
  6. OECD (2004) The 2004 OECD List of High Production Volume Chemicals Environment Directorate 
  7. Judson RS et al. (2018) New approach methods for testing chemicals for endocrine disruption potential. Current Opinion in Toxicology 9: 40-47 doi: 0.1016/j.cotox.2018.10.002
  8. NC3Rs (2017) RespiraTox: In silico model for predicting human respiratory irritation.
  9. OECD (2018) Test No. 414: Prenatal Developmental Toxicity Study, OECD Guidelines for the Testing of Chemicals, Section 4. doi: 10.1787/9789264070820-en
  10. OECD (2016) Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test, OECD Guidelines for the Testing of Chemicals, Section 4. doi: 10.1787/9789264264403-en
  11. OECD (2018) Test No. 443: Extended One-Generation Reproductive Toxicity Study, OECD Guidelines for the Testing of Chemicals, Section 4. doi: 0.1787/9789264185371-en
  12. OECD (2001) Test No. 416: Two-Generation Reproduction Toxicity, OECD Guidelines for the Testing of Chemicals, Section 4. doi: 10.1787/9789264070868-en
  13. OECD (2007) Principles for QSAR validation.

 

PDF - 142.94 KB